Advertisement

Vasodilators: Rationale and Practical Use

  • C. Perret
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 6)

Abstract

It was long considered that myocardial contractility was the main determinant of cardiac performance but in the last two decades it has become apparent that the pump function of the failing left ventricle is critically dependent upon loading conditions and, particularly, upon left ventricular outflow resistance [1]. Vasodilation is now commonplace in cardiac therapy. A number of vasodilator agents have been investigated and their specific advantages for the treatment of acute or chronic heart failure have been evaluated [2–7]. This has been greatly facilitated by the availability of reliable invasive and noninvasive techniques such as balloon-flotation catheter, echocardiography and radionuclide cardiac imaging, which are of particular interest for monitoring at the bedside the hemodynamic response in acute heart failure.

Keywords

Chronic Heart Failure Systemic Vascular Resistance Filling Pressure Acute Heart Failure Acute Pulmonary Edema 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ross J Jr, Braunwald E (1964) The study of left ventricular function in man by increasing resistance to ventricular ejection with angiotensin. Circulation 29: 739–749PubMedGoogle Scholar
  2. 2.
    Chatterjee K, Parmley WW (1977) The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis 19: 301–325PubMedCrossRefGoogle Scholar
  3. 3.
    Mason DT (1978) Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure. Am J Med 65: 106–111PubMedCrossRefGoogle Scholar
  4. 4.
    Weber S, Merillon JP, Prasquier R, Charbonneau P, Gourgon R (1980) Bases physiopathologiques et indications de l’utilisation des vasodilatateurs dans l’insuffisance ventriculaire gauche. Ann Med Interne 131: 43–55Google Scholar
  5. 5.
    Ribner HS, Bresnahan D, Hsieh AM, et al (1982) Acute hemodynamic responses to vasodilator therapy in congestive heart failure. Prog Cardiovasc Dis 25: 1–42PubMedCrossRefGoogle Scholar
  6. 6.
    Perret C (1983) Place des vasodilatateurs dans le traitement de l’insuffisance cardiaque. In: Masson (ed) Le traitement moderne de l’insuffisance cardiaque, 1st edn. Paris, pp 17–40Google Scholar
  7. 7.
    Opie LH (1987) Drugs for the heart. 2nd expanded ed. Grune and Stratton, OrlandoGoogle Scholar
  8. 8.
    Zelis R, Flaim SF (1982) Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis 24: 437–459PubMedCrossRefGoogle Scholar
  9. 9.
    Minami M, Yasuda H, Yamazaki N, et al (1983) Plasma norepinephrine concentration and plasma dopamine-beta-hydroxylase activity in patients with congestive heart failure. Circulation 67: 1324–1329PubMedCrossRefGoogle Scholar
  10. 10.
    Levine TB, Francis GS, Goldsmith SR, Simon A, Cohn JN (1982) Activity of the sympathetic nervous system and renin-angiotension system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49: 1659–1666PubMedCrossRefGoogle Scholar
  11. 11.
    Vaney C, Waeber B, Turini G, Margalith D, Brunner HR, Perret C (1984) Renin and the complications of acute myocardial infarction. Chest 86: 40–43PubMedCrossRefGoogle Scholar
  12. 12.
    Chidsey CA, Braunwald E, Morrow AG, Mason DT (1963) Myocardial norepinephrine concentrations in man. Effects of reserpine and congestive heart failure. N Engl J Med 269: 653–658PubMedCrossRefGoogle Scholar
  13. 13.
    Colucci W, Alexander RW, Williams GH, et al (1981) Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med 305: 185–190PubMedCrossRefGoogle Scholar
  14. 14.
    Bristow MR, Ginsburg R, Minobe W, et al (1982) Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human heart. N Engl J Med 307: 205–211PubMedCrossRefGoogle Scholar
  15. 15.
    Cohn JN (1986) Vasodilator therapy of dilated cardiomyopathy. Postgrad Med J 62: 599–600PubMedCrossRefGoogle Scholar
  16. 16.
    Packer M (1984) Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. Advocacy of a pragmatic approach to the selection of a therapeutic agent. Am J Med 76 (6A): 3–13PubMedCrossRefGoogle Scholar
  17. 17.
    Goldstein RE (1982) Coronary vascular responses to vasodilator drugs. Prog Cardiovasc Dis 24: 419–436PubMedCrossRefGoogle Scholar
  18. 18.
    Greenberg H, Dwyer EM, Jameson AG, Pinkernell BH (1975) Effects of nitroglycerin on the major determinants of myocardial oxygen consumption. Am J Cardiol 36: 426–432PubMedCrossRefGoogle Scholar
  19. 19.
    Bussmann WD, Passek D, Seidel W, Kaltenbach M (1981) Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation 63: 615–622PubMedCrossRefGoogle Scholar
  20. 20.
    Verma SP, Silke B, Nelson GIC, Hussain M, Richmond A, Taylor SH (1985) Haemodynamic advantages of a combined inotropic/venodilator regimen over inotropic monotherapy in acute heart failure. J Cardiovasc Pharmacol 7: 943–947PubMedCrossRefGoogle Scholar
  21. 21.
    Chatterjee K, Ports TA, Parmley WW (1981) Use of vasodilators in heart failure. In: Donoso E (ed) Advances and controversies in cardiology. Thieme–Stratton Inc, pp 8–193Google Scholar
  22. 22.
    Mann T, Cohn PF, Holman BL, Green LH, Markis JE, Phillips DA (1978) Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation 57: 732–738PubMedGoogle Scholar
  23. 23.
    Villani F, Perret C, Jequier E, Schelling JL (1974) Effect of phentolamine on peripheral venous distensibility in congestive heart failure. Eur J Clin Pharmacol 7: 11–16PubMedCrossRefGoogle Scholar
  24. 24.
    Gould L, Reddy CVR, Kalanithi P, Espina L, Gomprecht RF (1974) Use of phentolamine in acute myocardial infarction. Am Heart J 88: 144–148PubMedCrossRefGoogle Scholar
  25. 25.
    Perret C, Gardaz JP, Reynaert M, Grimbert F, Enrico GF (1975) Phentolamine for vasodilator therapy in left ventricular failure complicating acute myocardial infarction. Br Heart J 37: 640–646PubMedCrossRefGoogle Scholar
  26. 26.
    O’Rourke RA, Walsh RA (1987) Experience with calcium antagonist drugs in congestive heart failure. Am J Cardiol 59: 64B - 69BPubMedCrossRefGoogle Scholar
  27. 27.
    Sorkin EM, Clissold SP, Brogden RN (1985) Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in ischemic heart disease, hypertension and related cardiovascular diseases. Drugs 30: 182–274PubMedCrossRefGoogle Scholar
  28. 28.
    Packer M, Kessler PD, Hung Lee W (1987) Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 75 (suppl V): V56 - V64PubMedGoogle Scholar
  29. 29.
    Kiowski W, Erne P, Pfisterer M, Mueller J, Buehler FR, Burkart F (1987) Arterial vasodilator, systemic and coronary hemodynamic effects of nisoldipine in congestive heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 59: 1118–1125PubMedCrossRefGoogle Scholar
  30. 30.
    Opie LH, Phil D, Commerford PJ (1988) The total vascular burden, peripheral and coronary: vasodilator effects of nifedipine. Am Heart J 115: 228–238PubMedCrossRefGoogle Scholar
  31. 31.
    Cody RJ (1984) Angiotensin II-mediated vasoconstriction in chronic congestive heart failure, and response to converting enzyme inhibition. Am J Med 72 (2A): 71–77Google Scholar
  32. 32.
    Romankiewicz JA, Brogden RN, Heel RC, Speight TM, Avery GS (1983) Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs 25: 6–40PubMedCrossRefGoogle Scholar
  33. 33.
    Rademaker M, Shaw TRD, Williams BC, et al (1986) Intravenous captopril treatment in patients with severe cardiac failure. Br Heart J 55: 187–190PubMedCrossRefGoogle Scholar
  34. 34.
    Gomez HJ, Cirillo VJ, Irvin JD (1985) Enalapril: a review of human pharmacology. Drugs 30 (suppl 1): 13–24PubMedCrossRefGoogle Scholar
  35. 35.
    The Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 316: 1429–1435CrossRefGoogle Scholar
  36. 36.
    Brivet F, Delfraissy JF, Giudicelli JF, Richer C, Legrand A, Dormont J (1981) Immediate effects of captopril in acute left ventricular failure secondary to myocardial infarction. Eur J Clin Invest 11: 369–373PubMedCrossRefGoogle Scholar
  37. 37.
    Hornung RS, Hillis WS (1987) The acute haemodynamic effects of intravenous enalaprilic acid (MK422) in patients with left ventricular dysfunction. Br J Clin Pharmacol 23: 29–33PubMedGoogle Scholar
  38. 38.
    Colucci WS, Wright RF, Braunwald E (1986) New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. N Engl J Med 314:1st part 290–299; 2nd part 349–357Google Scholar
  39. 39.
    Benotti JR, Grossman W, Braunwald E, Carabello BA (1980) Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 62: 28–34PubMedGoogle Scholar
  40. 40.
    Wilmshurst PT, Thompson DS, Jenkins BS, Coltart DJ, Webb-Peploe MM (1983) Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. Br Heart J 49: 77–82PubMedCrossRefGoogle Scholar
  41. 41.
    Franciosa JA (1985) Intravenous amrinone: an advance or a wrong step? Ann Intern Med 102: 399–400PubMedGoogle Scholar
  42. 42.
    Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS (1985) Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure: dose-response relationships and comparison to nitroprusside. J Clin Invest 75: 643–649PubMedCrossRefGoogle Scholar
  43. 43.
    Monrad ES, Bairn DS, Smith HS, Lanoue A, Braunwald E, Grossman W (1985) Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 71: 972–979PubMedCrossRefGoogle Scholar
  44. 44.
    Brown RA, Dixon J, Farmer JB, et al (1985) Dopexamine: a novel agonist at peripheral dopamine receptors and beta-2-adrenoceptors. Br J Pharmacol 85: 599–608PubMedGoogle Scholar
  45. 45.
    Jaski BE, Wijns W, Foulds R, Serruys PW (1986) The haemodynamic and myocardial effects of dopexamine: a new beta-2-adrenoceptor and dopaminergic agonist. Br J Clin Pharmacol 21: 393–400PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • C. Perret

There are no affiliations available

Personalised recommendations